Update of the worldwide FDA study of the 3M diffractive multifocal intraocular lens

The multifocal diffractive intraocular lens (IOL) represents a significant technological advance. Results of 671 patients with a year follow-up from a worldwide study are presented. Through this FDA study, it appears that many patients can enjoy uncompromising distance vision as well as unaided near vision. With careful surgical control of astigmatism and competent calculation of IOL power, it may be possible to reduce the post-cataract patients' dependency on glasses.